Immune Design Corp.
IMDZ
IMDZ was delisted on the 1st of April, 2019.
64 hedge funds and large institutions have $39M invested in Immune Design Corp. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 16 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 71 → 64 (-7)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
49% less capital invested
Capital invested by funds: $76.9M → $39M (-$37.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.84M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$916K |
| 3 |
Renaissance Technologies
New York
|
+$656K |
| 4 |
Two Sigma Investments
New York
|
+$477K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.74M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.13M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$806K |
| 5 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$431K |
IMDZ Hedge Fund Activity: Q4 2018 in Review
64 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q4 2018, worth a combined $39M — down 49% from $76.9M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IMDZ and 10 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 28 added.
The largest buyer was EcoR1 Capital, adding an estimated $5.84M. The largest seller was Portolan Capital Management, exiting entirely with an estimated $2.5M sold.
- 64 institutional investors held Immune Design Corp. (IMDZ) as of Q4 2018, down from 71 in Q3 2018.
- Funds reported $39M of Immune Design Corp. stock for Q4 2018, down 49% quarter-over-quarter.
- 10 funds opened new Immune Design Corp. positions in Q4 2018 and 16 closed out, a net change of -6 holders.
- The largest Immune Design Corp. buyer in Q4 2018 was EcoR1 Capital, an estimated $5.84M added.
- The largest Immune Design Corp. seller in Q4 2018 was Portolan Capital Management, an estimated $2.5M sold.
Based on aggregated 13F filings for Q4 2018.